Of all the U.S. SEC’s recent proposed rules to make going, and staying, public more attractive, perhaps the most beneficial for biopharma and med-tech startups is the amendment that would give public companies the flexibility to file semi-annual rather than quarterly reports, Ben Bradford, head of external affairs at Massbio, told BioWorld.

The April 2024 full U.S. FDA approval of Pfizer Inc. and Genmab A/S’ tissue factor-targeting antibody-drug conjugate Tivdak (tisotumab vedotin) for cervical cancer sparked interest from drug developers in the strategy, which has been known about for a while.

Biopharma financings across all categories totaled $59.76 billion on 567 deals in the first half (H1) of 2026, more than double H1 2025’s $29.53 billion across 501 transactions.

To Ivan Oransky, China’s paper-mill problem is best understood as an incentives story. “This is literally organized crime,” the Retraction Watch co-founder told BioWorld. “Follow the money. When there’s an opportunity to make money, they will find it, and if your whole career is based on how often you publish and what journals you publish in and how often you’re cited, it’s not surprising that leads to bad behavior.”

With more and more approved products, cell and gene therapies (CGTs) are moving from the initial stronghold in academic medical centers, and these complex biologics are now available across a wider network of treatment centers.

Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion. The figure reflects a sector that is holding well above the low years of 2022 and 2023.

Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of those deals topping $7.5 billion, up 23% from the year-ago semester and just slightly below H1 2024, which saw a total of $7.84 billion in large financings.